文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Friend or Foe - Tc17 cell generation and current evidence for their importance in human disease.

作者信息

Hipp Anna Veronika, Bengsch Bertram, Globig Anna-Maria

机构信息

Clinic for Internal Medicine II, Gastroenterology, Hepatology, Endocrinology, and Infectious Diseases, University Medical Center Freiburg, Faculty of Medicine, Freiburg, Germany.

出版信息

Discov Immunol. 2023 Jul 20;2(1):kyad010. doi: 10.1093/discim/kyad010. eCollection 2023.

DOI:10.1093/discim/kyad010
PMID:38567057
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10917240/
Abstract

The term refers to interleukin 17 (IL-17)-producing CD8 T cells. While IL-17 is an important mediator of mucosal defense, it is also centrally involved in driving the inflammatory response in immune-mediated diseases, such as psoriasis, multiple sclerosis, and inflammatory bowel disease. In this review, we aim to gather the current knowledge on the phenotypic and transcriptional profile, the and generation of Tc17 cells, and the evidence pointing towards a relevant role of Tc17 cells in human diseases such as infectious diseases, cancer, and immune-mediated diseases.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8c7/10917240/3270326ecb9c/kyad010_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8c7/10917240/3270326ecb9c/kyad010_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8c7/10917240/3270326ecb9c/kyad010_fig1.jpg

相似文献

[1]
Friend or Foe - Tc17 cell generation and current evidence for their importance in human disease.

Discov Immunol. 2023-7-20

[2]
Tc17 biology and function: Novel concepts.

Eur J Immunol. 2020-9

[3]
MCAM+CD161- Th17 Subset Expressing CD83 Enhances Tc17 Response in Psoriasis.

J Immunol. 2023-6-15

[4]
IL-17A-producing CD8(+)T cells as therapeutic targets in autoimmunity.

Expert Opin Ther Targets. 2015-5

[5]
Pleural mesothelial cells promote expansion of IL-17-producing CD8+ T cells in tuberculous pleural effusion.

J Clin Immunol. 2013-1-9

[6]
Interleukin-24 Limits Tumor-Infiltrating T Helper 17 Cell Response in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma.

Viral Immunol. 2022-4

[7]
Loss of IL-17-producing CD8 T cells during late chronic stage of pathogenic simian immunodeficiency virus infection.

J Immunol. 2010-12-10

[8]
Tc17 Cells in Immunity and Systemic Autoimmunity.

Int Rev Immunol. 2015

[9]
Increased IL-17 and/or IFN-γ producing T-cell subsets in gut mucosa of long-term-treated HIV-1-infected women.

AIDS. 2019-3-15

[10]
Increased number of Tc17 and correlation with Th17 cells in patients with immune thrombocytopenia.

PLoS One. 2011-10-24

引用本文的文献

[1]
Persistent reduction of in the infant gut microbiome in the first year of age following penicillin prophylaxis for maternal GBS colonization.

Front Immunol. 2025-5-15

[2]
PD-1 blockade employed at the time CD8+ T cells are activated enhances their antitumor efficacy.

J Immunother Cancer. 2025-5-7

[3]
Sex-dependent modulation of T and NK cells and gut microbiome by low sodium diet in patients with primary aldosteronism.

Front Immunol. 2024-12-19

[4]
Mouse CD8+ T cell subsets differentially generate IL-17-expressing cells in the colon epithelium and lamina propria.

Clin Exp Immunol. 2025-1-21

[5]
Adapting for success: T cell features at tissue sites.

Discov Immunol. 2024-5-18

本文引用的文献

[1]
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).

Lancet. 2023-1-7

[2]
CD6-mediated inhibition of T cell activation via modulation of Ras.

Cell Commun Signal. 2022-11-21

[3]
IFNγIL-17 CD8 T cells contribute to immunosuppression and tumor progression in human hepatocellular carcinoma.

Cancer Lett. 2023-1-1

[4]
scRNA-seq of gastric tumor shows complex intercellular interaction with an alternative T cell exhaustion trajectory.

Nat Commun. 2022-8-23

[5]
IL-17 and IL-17-producing cells in protection versus pathology.

Nat Rev Immunol. 2023-1

[6]
High-dimensional profiling reveals Tc17 cell enrichment in active Crohn's disease and identifies a potentially targetable signature.

Nat Commun. 2022-6-27

[7]
Exhaustion of CD39-Expressing CD8 T Cells in Crohn's Disease Is Linked to Clinical Outcome.

Gastroenterology. 2022-10

[8]
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.

Lancet. 2022-5-28

[9]
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.

Lancet. 2022-5-28

[10]
LLT1-CD161 Interaction in Cancer: Promises and Challenges.

Front Immunol. 2022

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索